Toggle Main Menu Toggle Search

Open Access padlockePrints

Identification of prognostic biomarkers in a large cohort of patients with LGMD R2

Lookup NU author(s): Carla Bolaño DiazORCiD, Jose Verdú-DíazORCiD, Dr Dan HaoORCiD, Meredith JamesORCiD, Professor Andrew BlamireORCiD, Heather Hilsden, Professor Volker StraubORCiD, Professor Jordi Diaz ManeraORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2026. The Author(s).BACKGROUND: Limb-girdle muscular dystrophy R2-dysferlin related (LGMD-R2) is a progressive muscle condition with marked variability in disease course, making prognosis challenging. Quantitative MRI (qMRI) has emerged as a complementary tool that may detect progression earlier and more precisely. Integrating different data modalities is challenging with conventional approaches, and artificial intelligence (AI) can help overcome this. Our aim is to develop robust models capable of predicting clinical progression in LGMD-R2 by incorporating AI-based techniques into the analysis pipeline. METHODS: Data from 188 COS 1 participants were analysed. Disease progression was assessed using the North Star Assessment for Limb Girdle type Muscular Dystrophies (NSAD). Ambulatory individuals with a maximum NSAD ≥ 20 were included, and progression trajectories were identified through hierarchical clustering. Feature selection was performed using a machine learning pipeline, and top predictors were entered into stepwise logistic regression to build clinical-only and combined clinical-MRI models. RESULTS: Two stages of progression were identified, a fast one with a mean three-year loss of 14.4 NSAD points, and a moderate one, with a mean loss of 3.8 NSAD points. The combined model achieved better balanced accuracy than the clinical-only one (83.7% vs 78.7%). Key predictors in the combined model were disease duration and fat content measures in the anterior thigh and gracilis muscle, while the clinical model included disease duration, creatine phosphokinase (CK), and 10 m walk/run test velocity. CONCLUSIONS: Progression in LGMD-R2 can be grouped into distinct clinical trajectories. Individuals at a faster stage of progression were younger, had shorter disease duration, higher CK, greater weakness, and relatively preserved vastus intermedius and gracilis muscles. AI enabled efficient integration of heterogeneous data, and qMRI biomarkers provided complementary information that improved predictive accuracy.


Publication metadata

Author(s): Bolano-Diaz CF, Verdu-Diaz J, Hao D, James MK, Rufibach L, Blamire A, Reyngoudt H, Carlier PG, Gordish-Dressman H, Hilsden H, Spuler S, Day J, Jones KJ, Bharucha-Goebel D, Pestronk A, Walter MC, Paradas C, Stojkovic T, Mori-Yoshimura M, Bravver E, Pegoraro E, Mendell J, Straub V, Diaz-Manera J

Publication type: Article

Publication status: Published

Journal: Journal of Neurology

Year: 2026

Volume: 273

Issue: 6

Online publication date: 26/05/2026

Acceptance date: 10/05/2026

ISSN (print): 0340-5354

ISSN (electronic): 1432-1459

Publisher: Springer Nature

URL: https://doi.org/10.1007/s00415-026-13868-0

DOI: 10.1007/s00415-026-13868-0

PubMed id: 42189263


Altmetrics

Altmetrics provided by Altmetric


Share